Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Catia Cilloniz Campos (Barcelona, Spain), Catia Cilloniz Campos, Albert Gabarrus, Adamanthia Liapikou, Daniel Martinez, Michael Niederman, Antoni Torres. Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa. Eur Respir J 2016; 48: Suppl. 60, 608

Member's Comments

No comment yet.

Related content which might interest you: Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010 Multidrug-resistant bacteria in community-acquired pneumonia Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017 What is MRSA? Source: Eur Respir J 2009; 34: 1190-1196 Year: 2009 Pseudomonas, enterobacteriaceae ESBL positive and staphylococcus MRSA: When to suspect them in CAP? Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Pseudomonas aeruginosa pneumonia in the community Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Potential treatment for nosocomial respiratory strains of extreme drug resistant acinetobacter baumanii Source: Eur Respir J 2007; 30: Suppl. 51, 410s Year: 2007 Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Aetiopathogenesis of VAP revisited Source: Eur Respir Mon 2011; 53: 1-10 Year: 2011 Molecular mechanisms and virulence of colistin-resistant klebsiella pneumoniae Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Antibiotic resistance and nosocomial pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Pulmonary infections with pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 642s Year: 2004 Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Frequency of multidrug resistant pathogens in healthcare associated pneumonia Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Bacterial community-acquired pneumonia Source: Eur Respir Monogr 2014; 66: 98-111 Year: 2014 The effect of macrolide-resistance on the outcome of patients hospitalized for streptococcus pneumoniae pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Source: Eur Respir J 2007; 29: 548-560 Year: 2007 MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009